These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 8012063)

  • 1. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
    Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
    Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
    Cimoli G; Valenti M; Noviello E; Parodi S; Mazzoni A; Rovini E; De Sessa F; Russo P
    J Cancer Res Clin Oncol; 1995; 121(3):155-63. PubMed ID: 7713987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells.
    Cimoli G; Valenti M; Venturini M; Conte P; Russo P
    Anticancer Res; 1992; 12(5):1411-4. PubMed ID: 1444198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circumvention of atypical multidrug resistance with tumor necrosis factor.
    Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
    Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S; Austin CA; Fisher LM
    Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
    J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
    Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells.
    Mazzoni A; Trave F
    Oncol Res; 1993; 5(2):75-82. PubMed ID: 8364256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
    Orengo G; Noviello E; Cimoli G; Pagnan G; Parodi S; Venturini M; Conte P; Schenone F; Conzi G; Russo P
    Jpn J Cancer Res; 1992 Nov; 83(11):1132-6. PubMed ID: 1336489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines.
    Russo P; Parodi S; Billi G; Oliva C; Venturini M; Noviello E; Conte P
    Jpn J Cancer Res; 1992 Jul; 83(7):684-7. PubMed ID: 1517145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines.
    Debernardis D; Stanzione S; Ottoboni C; Clerico L; Mancuso T; Parodi S; Russo P
    J Pharmacol Exp Ther; 1996 Oct; 279(1):84-90. PubMed ID: 8858979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
    Webb CD; Latham MD; Lock RB; Sullivan DM
    Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
    Safrit JT; Berek JS; Bonavida B
    Gynecol Oncol; 1993 Feb; 48(2):214-20. PubMed ID: 8428693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.